Initial experience of 980-nm diode laser treatment for recurrent non-muscle-invasive bladder cancer.

Introduction: Laser ablation using a 980-nm wavelength diode laser, which is a new-generation laser, for recurrent bladder cancer is known to have a lower incidence of complications and recurrence than conventional transurethral resection of bladder tumor surgery. This is the first study to report the use of 980-nm diode laser ablation for recurrent non-muscle-invasive bladder cancer in Japan.

Case Presentation: A 73-year-old man underwent transurethral laser ablation for the treatment of recurrent non-muscle-invasive bladder cancer.

Comprehensive genomic profiling of primary bladder mucinous adenocarcinoma, a rare genitourinary cancer: A case report.

Primary bladder mucinous adenocarcinoma is a rare genitourinary cancer. Here, we present the case of a 75-year-old woman where pathological and imaging findings led to the diagnosis of primary bladder mucinous adenocarcinoma. She underwent treatment with paclitaxel-ifosfamide-cisplatin (TIP).

Autologous rectus abdominis fascia sling surgery following unsuccessful synthetic midurethral sling.

Introduction: We performed autologous rectus abdominis fascia sling surgery using Advantage™ following an unsuccessful synthetic midurethral sling.

Case Presentation: At the age of 76 years, the patient experienced stress urinary incontinence recurrence. A 1-h pad test resulted in 259 g of leakage.

A new method for effective use of the ClearPetra ureteral access sheath for a giant ureteral stone.

The ClearPetra (Well Lead Medical, Guangzhou, China) has recently entered the market, enabling continuous stone fragmentation and removal while maintaining a continuous perfusion field of view. The efficacy and safety of the ClearPetra renal access sheath (RAS) in percutaneous nephrolithotomy (PCNL) and endoscopic combined intrarenal surgery (ECIRS) have been reported. However, no reports have described the use of the ClearPetra ureteral access sheath (UAS).